NCT06304233

The Protein Disrupted in Schizophrenia 1 (DISC1) as a Novel Biomarker for Cardiac Disease

The Protein Disrupted in Schizophrenia 1 (DISC1) as a Novel Biomarker for Cardiac Disease - The Link Between DISC1 and Cardiac Function in Patients With Schizophrenia

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 120 (estimated)
• Sponsor: Norwegian University of Science and Technology · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

To study the association between DISC1 RNA expression levels and cardiac function in patients with schizophrenia.

Detailed description

Potential participants interested in the study will be screened for eligibility. Those who meet the eligibility criteria will be informed about the study, the expected investigations and its potential risks. All participants giving written informed consent will be enrolled into the study. Participants will be interviewed, given questionnaires, have blood and/or skin samples and clinical parameters taken. Cardiac function parameters will be measured using electrocardiography, echocardiography and magnetic resonance imaging.

Conditions

• Heart Diseases
• Heart; Functional Disturbance
• Schizophrenia

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Echocardiography	ultrasound assessment of heart structure, volume and function
DIAGNOSTIC_TEST	Cardiac Magnetic Resonance Imaging	MRI assessment of heart structure, volume, function and tissue characteristics
DIAGNOSTIC_TEST	Electrocardiography	Assessment of cardiac rhythm and electrical activity
OTHER	Blood sampling	To measure DISC1 mRNA expression and other potential biomarkers

Timeline

• Start date: 2023-12-13
• Primary completion: 2026-12-01
• Completion: 2038-06-01
• First posted: 2024-03-12
• Last updated: 2025-06-22

Locations

2 sites across 1 country: Norway